Research Site

East Melbourne 3002

8 studies enrolling now · 17 studies all time

What they study most

Atopic Dermatitis, Breast Cancer, Colorectal Cancer, ER+ HER2- Advanced Breast Cancer, Endometrial Cancer, Gastric Cancer/Gastroesophageal Junction Cancer, Geographic Atrophy, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, High Grade Serous Ovarian Carcinoma, High-grade Serous Ovarian Cancer (HGSOC), Melanoma

Studies at this site

• A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors — Recruiting now
• A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer — Recruiting now
• A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors — Recruiting now
• DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer — Recruiting now
• A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer — Recruiting now
• Study of AZD0754 in Participants With Metastatic Prostate Cancer — Recruiting now
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer — Running, not enrolling
• A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma — Starting soon
• A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer — Running, not enrolling
• Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer — Running, not enrolling
• A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early
• A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition — Running, not enrolling
• LTFU for All Cell and Gene Therapy Studies — Starting soon
• Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis — Completed
• Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer — Completed
• Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis — Completed
• First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX — Completed